Back to top
more

Xencor (XNCR)

(Real Time Quote from BATS)

$19.40 USD

19.40
153,629

+0.05 (0.26%)

Updated Jun 26, 2024 03:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

MorphoSys BLA for Cancer Drug Gets Priority Review from FDA

by Zacks Equity Research

MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.

Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.

Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

by Zacks Equity Research

Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

Company News For Dec 30, 2019

by Zacks Equity Research

Companies in the news are: MIK, XNCR, PT, FCEL

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 68.97% and 371.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 33.33% and 156.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Jumps: Stock Rises 7.4%

by Zacks Equity Research

Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Company News For Jun 26, 2019

by Zacks Equity Research

Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION

Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 220.93% and 86.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Partnerships and agreements are likely to drive Nielsen's (NLSN) fourth-quarter 2018 revenues. However, weakness in the Buy segment and increasing competition may impact its profits.

What's in Store for Booking Holdings' (BKNG) Q4 Earnings?

by Zacks Equity Research

Booking Holdings' (BKNG) Q4 earnings are likely to reflect growth in international markets.

Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Xencor Sees Hammer Chart Pattern: Time to Buy?

    Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Xencor (XNCR) delivered earnings and revenue surprises of 16.36% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC

      by Zacks Equity Research

      Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.

        Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC

        by Zacks Equity Research

        Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).

          Increased Earnings Estimates Seen for Xencor (XNCR): Can It Move Higher?

          by Zacks Equity Research

          Xencor (XNCR) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.

            Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

            by Zacks Equity Research

            Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).

              Novartis (NVS) Announces Positive Data on Heart Failure Drug

              by Zacks Equity Research

              Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.

                Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy

                by Zacks Equity Research

                Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.